Non-Hodgkins Lymphoma
Conditions
Brief summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Detailed description
Upon determination of eligibility, patients will receive: * Ifosfamide + Carboplatin + Etoposide + Rituximab Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.
Interventions
Sponsors
Biogen
SCRI Development Innovations, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be included in this study, you must meet the following criteria: * Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma * Persistent lymphoma after one or two previous chemotherapy regimens * Patients should not be considered candidates for high-dose chemotherapy * Ability to perform activities of daily living with assistance * Measurable or evaluable disease * Age \> 18 years * Adequate bone marrow, liver and kidney function
Exclusion criteria
You cannot participate in this study if any of the following apply to you: * Patients with impaired bone marrow reserve * Female patients who are pregnant or lactating * Serious active infection at the time of treatment * Any other serious underlying condition * Brain or meningeal) with lymphoma * HIV or AIDS-related lymphoma * Received external beam radiation therapy to \> 25% of active bone marrow. * History of other cancers, either active or treated Please note: There are additional inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival | — |
| overall survival | — |
Countries
United States
Outcome results
None listed